NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: NATCAPSUQ · data 2026-10-31
Natural Capsules Limited
In plain words
Price: 41.0% below its 52-week high of ₹234.
Delivery: 54.2% of traded shares were kept for delivery over the last 10 sessions, against 72.4% over the last 60.
Latest results: a net loss of ₹7 cr for the quarter ended Sept 2025.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹191 cr |
| Net profit (last 12 months) | ₹-22 cr |
| Sales growth, 3 years (yearly) | 3.2% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 50.9% (-0.3 pts in a year), pledged 0.0%, institutions 0.1%.
ROE -7.5%, ROCE -6.4%, operating margin -9.4%: how much profit it earns on the money it uses.
Debt/equity 0.52, Profit growth — and sales growth 3.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-7.5%).
- Thin operating margin (-9.4%).
- Slow sales growth (3.2% a year over 3 years).
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY26)
NATCAPSUQ Q2 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹45.8 crore.
Net loss was ₹6.99 crore.
Operating margin was 1.9%.
EPS was -₹6.76.
NATCAPSUQ के Q2 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹45.8 करोड़।
शुद्ध घाटा: ₹6.99 करोड़।
ऑपरेटिंग मार्जिन: 1.9%।
EPS: -₹6.76।
NATCAPSUQના Q2 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹45.8 કરોડ.
ચોખ્ખી ખોટ: ₹6.99 કરોડ.
ઓપરેટિંગ માર્જિન: 1.9%.
EPS: -₹6.76.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 13 Nov 25Results Q2 FY26 results: net profit −₹7 cr -0.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2025 | ₹46 cr | ₹-7 cr | — | -1.9% | -6.76 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 50.92% | 50.92% | 51.04% | 51.26% |
| Foreign institutions (FII) | 0.08% | — | 0.00% | 0.00% |
| Domestic institutions (DII) | — | — | 0.00% | 0.00% |
| Mutual funds | — | — | 0.00% | 0.00% |
| Retail investors | 22.47% | 22.91% | 23.05% | 24.12% |
| Number of shareholders | 8,724 | 8,756 | 8,850 | 9,075 |
Common questions
What was Natural Capsules Limited's latest quarterly profit?
Natural Capsules Limited reported a net loss of ₹7 cr for the quarter ended Sept 2025, on revenue of ₹46 cr.
How much do promoters hold in Natural Capsules Limited?
Promoters held 50.92% of Natural Capsules Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Natural Capsules Limited debt-free?
Its latest reported debt-to-equity ratio is 0.52.
What is the 52-week high and low of Natural Capsules Limited?
The 52-week high is ₹234 and the 52-week low is ₹132.02.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Natural Capsules Limited | ₹138.06 | ₹142 cr | — | — | -7.5% | -6.4% | 0.52 | -33.0% |
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
| Shri Ahimsa Naturals Limited | ₹399.9 | ₹952 cr | 32.1 | 4.8 | 16.7% | 18.4% | 0.1 | +55.0% |
| Influx Healthtech Limited | ₹264.5 | ₹612 cr | 28.3 | — | 30% | 38% | — | +48.4% |
| Lyka Labs Limited | ₹76.6 | ₹278 cr | — | — | -10.2% | -9.9% | 0.53 | -20.6% |
| Sat Kartar Life Limited | ₹130 | ₹205 cr | 10.7 | 2.4 | 28.7% | 34.8% | 0.04 | -28.2% |
Compare NATCAPSUQ with AMRUTANJAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NATCAPSUQ in NSE Scanner →